Bayer (BAYN) Given a €69.00 Price Target at Warburg Research

Warburg Research set a €69.00 ($80.23) price objective on Bayer (FRA:BAYN) in a report released on Thursday morning, Borsen Zeitung reports. The firm currently has a neutral rating on the healthcare company’s stock.

BAYN has been the subject of several other research reports. Societe Generale set a €65.00 ($75.58) price objective on shares of Bayer and gave the stock a neutral rating in a research report on Wednesday, March 27th. UBS Group set a €110.00 ($127.91) price objective on shares of Bayer and gave the stock a buy rating in a research report on Monday, February 4th. DZ Bank restated a buy rating on shares of Bayer in a research report on Monday, March 11th. Baader Bank set a €123.00 ($143.02) price objective on shares of Bayer and gave the stock a buy rating in a research report on Friday, January 18th. Finally, Nord/LB set a €72.00 ($83.72) price objective on shares of Bayer and gave the stock a neutral rating in a research report on Wednesday, February 27th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and twelve have issued a buy rating to the company’s stock. Bayer has a consensus rating of Hold and an average price target of €82.07 ($95.42).

Shares of FRA:BAYN opened at €58.74 ($68.30) on Thursday. Bayer has a twelve month low of €91.58 ($106.49) and a twelve month high of €123.82 ($143.98).

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Featured Article: Investing in Blue-Chip Stocks

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.